In the midst of a big clear-out of drawers and cupboards you rarely venture into, you'll probably find a little more than you bargained for. Perhaps you didn't realize just how many VHS tapes you ...

A soldier wounded in Korea in 1951 had better survival odds than soldiers wounded in World War II despite heavier casualties and harsher conditions. The difference was time. Mobile Army Surgical ...

EXCLUSIVE: The 1962 song “Monster Mash,” which has become an annual Halloween +hit, is becoming an animated movie at Miramax. Miramax CEO Jonathan Glickman, who has been behind such haunted hits as ...

For years, MASH was where drug development dreams went to die. One trial after another failed. Companies bowed out. The field earned a reputation as one of biopharma’s most intractable challenges: a ...

Metabolic-associated steatohepatitis (MASH) happens when excess fat in the liver causes inflammation and scarring, or fibrosis. The condition is serious, and when left untreated it can lead to ...

There are two FDA-approved medications for the metabolic disorder known as MASH. Roche is paying $2.4 billion to acquire 89bio and its late-stage MASH drug, giving the Swiss pharmaceutical giant the ...

Roche dived into the metabolic dysfunction-associated steatohepatitis (MASH) space by agreeing to hand over up to $3.5 billion for 89bio and its phase-3-stage candidate for the fatty liver disease. At ...

NEW YORK, NEW YORK - JUNE 21: Dan Marino speaks onstage at Fanatics Fest NYC 2025 at Javits Center on June 21, 2025 in New York City. (Photo by Slaven Vlasic/Getty Images) To say that Dan Marino has ...

Add Yahoo as a preferred source to see more of our stories on Google. Alan Alda has never been easy to pin down. For millions, he’ll always be Hawkeye Pierce, the wisecracking yet deeply human surgeon ...

MASH prevalence and advanced disease cases are expected to rise significantly by 2040, with Brazil and Saudi Arabia seeing the highest increases. The US is projected to have the highest mortality ...

Drug developers with products targeting a liver condition called metabolic dysfunction-associated steatohepatitis (MASH) traded higher on Wednesday after the U.S. FDA said it has accepted an ...